Our data suggest that aminobisphosphonates should be tested in a combination strategy for HCC, to overcome two key limiting factors: their direct delivery to the tumour can enhance IPP expression to increase in situ activation of Vγ9Vδ2 T-cells, whilst their use for large-scale expansion of blood Vγ9Vδ2 T-cells can expand a population with enhanced cytotoxicity and the tissue-retention properties of TRM to replenish depleted numbers within the tumour. This evidence concerns the gene IPP and hepatocellular carcinoma.